Article Text
Abstract
The UK Renal Registry currently collects information on UK children with kidney failure requiring long-term kidney replacement therapy (KRT), which supports disease surveillance and auditing of care and outcomes; however, data are limited on children with chronic kidney disease (CKD) not on KRT.
Methods In March 2020, all UK Paediatric Nephrology centres submitted data on children aged <16 years with severely reduced kidney function as of December 2019, defined as an estimated glomerular filtration rate <30 mL/min/1.73 m2.
Results In total, 1031 children had severe CKD, the majority of whom (80.7%) were on KRT. The overall prevalence was 81.2 (95% CI 76.3 to 86.3) per million of the age-related population.
Conclusions The prevalence of severe CKD among UK children is largely due to a high proportion of children on long-term KRT. Expanding data capture to include children with CKD before reaching failure will provide greater understanding of the CKD burden in childhood.
- Paediatrics
- Nephrology
- Epidemiology
This article is made freely available for personal use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.
https://bmj.com/coronavirus/usageStatistics from Altmetric.com
Footnotes
Twitter @ledicmucy
Contributors LP, SM, CI, DN and JM designed and coordinated the data collection process in response to COVID-19 infection concerns for children with kidney disease; CI, MC, S Haq, S Hegde, AL, MM, HM, MM, SM, BR, MDS, KT and DW collated centre data; WM and AC analysed data; LP drafted and revised the manuscript with intellectual input from the authors.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests LP declares funding from the National Institute for Health Research (NIHR) and Kidney Research UK (KRUK). BCR declares funding from KRUK, honoraria from Alexion Pharmaceuticals and Magnolia Innovation, and consultancy payment from Chiesi. MM reports previous honoraria and travel expenses from Alexion. SM declares a role as head of the UK Renal Registry Audit and Informatics group. KT declares a role as clinical lead of the National Institute for Health and Care Excellence Medical Technologies Advisory Committee during the study period. DN declares funding/payment from the Health Foundation, UK Kidney Association, Chiang Mai University and GSK.
Provenance and peer review Not commissioned; externally peer reviewed.